Axq Capital, LP 4 D Molecular Therapeutics, Inc. Transaction History
Axq Capital, LP
- $222 Billion
- Q4 2024
A detailed history of Axq Capital, LP transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Axq Capital, LP holds 19,753 shares of FDMT stock, worth $96,394. This represents 0.05% of its overall portfolio holdings.
Number of Shares
19,753Holding current value
$96,394% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding FDMT
# of Institutions
146Shares Held
46.7MCall Options Held
121KPut Options Held
33.2K-
Black Rock Inc. New York, NY4.9MShares$23.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.56MShares$22.3 Million0.41% of portfolio
-
Goldman Sachs Group Inc New York, NY4.27MShares$20.9 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY2.95MShares$14.4 Million2.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.86MShares$14 Million0.0% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $158M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...